Pharmaceutical Technology

JUNE 18, 2025

Amid President Donald Trump’s stated desire to sharply reduce drug prices on the US market, India has also proposed to supply generic medicines at between 20% and 25% of the current reference branded prices, for three years after originator patent expiry.

Drug Pricing

PharmaTech

JUNE 30, 2025

The company has invested $4 billion in the past 15 years to expand its US operations, which began in 1991, and now has an annual domestic capacity to produce 12 billion finished doses of generic medicines. Hikma Publishes its 2024 Sustainability Report Reinforcing Commitment to Global Access to Medicines. Press Release.

Dosage

PharmaState Academy

JANUARY 29, 2024

Significance of the Indian Pharmaceutical Market: Discussing the Indian pharmaceutical market, Mr. Kapadia noted India’s status as the world’s largest exporter of generic medicines and third in terms of pharmaceutical production.

Generic Medicine

Express Pharma

AUGUST 4, 2024

To register or view the event programme click here. DIA is celebrating 60 years of bringing together leading minds to foster collaboration and advancement in global healthcare. Early-bird registration for the India Annual Meeting is available through August 10, 2024.

Generic Medicine

pharmaphorum

JANUARY 30, 2023

A spokesperson for the agency stated, “Shortages can have multiple causes, including manufacturing problems causing delays or interruption in the production, shortages of raw materials, increased demand of medicines, distribution problems, labour disruptions, and natural disasters.”

Generic Medicine

Express Pharma

DECEMBER 7, 2023

India Pharma Inc, hailed for its prowess in the production of high-quality generic medicines, now needs to shift from a conventional, volume-based business strategy to a value-based approach to keep it up its growth momentum. In this context, finding the right opportunities and understanding the challenges has become crucial.

Generic Medicine

pharmaphorum

OCTOBER 11, 2022

The Reuters Pharma event 2022 began as a bustling industry affair yesterday, based out of the Nice Acropolis convention centre on France’s balmy south coast. Indeed, of the 281 WHO-listed essential medicines, 100% of respiratory treatments are Teva’s. The patient, he said, is the most important part of that.

Generic Medicine

pharmaphorum

OCTOBER 26, 2021

Taking part in a fireside chat at the recent virtual Reuters Events: Pharma 2021 meeting, he explained how the COVID-19 pandemic had been a “wakeup call” for the industry, and spoke about the strategies that could help build the European healthcare systems of the future.

Generic Medicine

Quality Matters

NOVEMBER 27, 2023

The event engaged various experts representing Duke-Margolis, FDA, the American Society of Clinical Oncology, and many others who discussed data behind cancer drug shortages and needed next steps. DM: What are some of USP’s recent efforts to strengthen drug supply chains and address shortages?

Generic Medicine

European Pharmaceutical Review

FEBRUARY 2, 2023

This reliance on sourcing API from other nations puts Europe’s entire manufacturing cycle at risk, especially in the event of global crises and geopolitical tensions. Alarmingly, there are now 93 active ingredients for which no European company holds a certificate.

Generic Medicine

Quality Matters

JANUARY 23, 2023

Leveraging insights from data on USP standards distribution and usage at more than 22,000 locations worldwide and 40+ external data sets, USP launched the Medicine Supply Map in 2021 to provide an early-warning capability for supply chain vulnerabilities.

Generic Medicine

European Pharmaceutical Review

JULY 29, 2024

The Committee for Medicinal Products for Human Use (CHMP) has recommended against a marketing authorisation for Leqembi (lecanemab), as a treatment for Alzheimer’s disease, during its July meeting last week. Tuznue (trastuzumab) for breast and gastric cancer.

Generic Medicine

Quality Matters

MAY 22, 2023

Geographic concentration and drug shortages Drugs with greater geographic concentration in manufacturing of their active pharmaceutical ingredient (API) and/or finished dose form are known to be more susceptible to possible shortages due in part to the potential concentrated impact of external events like natural disasters (e.g.,

Generic Medicine

Quality Matters

APRIL 26, 2023

FDA are co-hosting the APEC Medical Product Supply Chain Dialogue as a signature event of the U.S. In my keynote remarks, I highlighted the following elements of a strong medicines supply chain. in a platform that assesses the vulnerability of specific medicines to supply chain disruptions. To advance this goal, USP and the U.S.

Prescription Filling

Pharmaceutical Technology

DECEMBER 19, 2022

While the ripple effect of such an event is expected across sectors, in the pharmaceutical arena, small and mid-sized enterprises (SMEs) are predicted to be heavily impacted as the economic downturn affects plans to raise capital, amongst other things. million as part of the Build Back Better Regional Challenge.

Pharmaceutical Companies

European Pharmaceutical Review

JULY 1, 2024

Additionally, approval was recommended two generic medicines: Enzalutamide Viatris (enzalutamide) to treat prostate cancer, and Nilotinib Accord (nilotinib) was also recommended to treat Philadelphia chromosome positive chronic myelogenous leukaemia.

Generic Medicine

Quality Matters

MAY 30, 2024

This briefing, widely attended with bipartisan representation, included panel discussions with key thought leaders and experts on the pharmaceutical supply chain to share insights that can help to prevent future shortages and improve access to critical medicines for all patients.

Generic Medicine

PharmaTech

AUGUST 7, 2025

Hikma Pharmaceuticals USA Announces $1 Billion of New US Investment to Further Expand its Domestic Manufacturing and Development of Essential Generic Medicines. July 21, 2025. Hikma Pharmaceuticals. Press Release. June 28, 2025.

Dosage

Quality Matters

MAY 18, 2023

Speaking as a fellow panelist at the event, I agreed standardization can have a significant role to play in helping with the regulatory aspects of AMT, particularly when the goal is to advance adoption of such technologies globally. The non-profit maker of essential generic medicines was established by a group of U.S.

Generic Medicine

European Pharmaceutical Review

APRIL 3, 2023

The committee adopted positive opinions for three generic medicines: Dabigatran Etexilate Accord (dabigatran etexilate) for the prevention of venous thromboembolic events Lacosamide Adroiq (lacosamide) for epilepsy Sugammadex Adroiq (sugammadex) for the reversal of neuromuscular blockade induced by rocuronium or vecuronium.

Chemotherapy

pharmaphorum

MAY 26, 2022

Factors such as ethnicity, gender, sexual orientation and age can contribute to interindividual differences in treatment responses and risks of adverse events. As a Non-Clinical Assessor at MHRA he assessed non-clinical data packages for new and generic medicines.

Packaging

PharmaTech

JULY 24, 2025

Generic medicines differently. Policies and levels and insurance, right? And so that really makes the market much more complex. Certain companies and organizations are advocating for the administration to treat. They're arguing that, they're, the margins are so low and the reimbursement rates aren't moving anywhere.

Dosage